Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
Data presentations at next week’s ASH meeting will be vital for Autolus to restore confidence in pipeline.